Rerouting the drug response: Overcoming metabolic adaptation in KRAS-mutant cancers.
Sci Signal
; 15(756): eabj3490, 2022 10 18.
Article
em En
| MEDLINE
| ID: mdl-36256706
ABSTRACT
Mutations in guanosine triphosphatase KRAS are common in lung, colorectal, and pancreatic cancers. The constitutive activity of mutant KRAS and its downstream signaling pathways induces metabolic rewiring in tumor cells that can promote resistance to existing therapeutics. In this review, we discuss the metabolic pathways that are altered in response to treatment and those that can, in turn, alter treatment efficacy, as well as the role of metabolism in the tumor microenvironment (TME) in dictating the therapeutic response in KRAS-driven cancers. We highlight metabolic targets that may provide clinical opportunities to overcome therapeutic resistance and improve survival in patients with these aggressive cancers.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Proteínas Proto-Oncogênicas p21(ras)
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article